EP1372644A2 - Verwendung substituierter imidazo[1,2-a]-pyridin-3-yl-amid-und imidazo[1,2-a]-pyridin-3-yl-aminverbindungen als arzneimittel zur behandlung von neurodegenerativen erkrankungen - Google Patents
Verwendung substituierter imidazo[1,2-a]-pyridin-3-yl-amid-und imidazo[1,2-a]-pyridin-3-yl-aminverbindungen als arzneimittel zur behandlung von neurodegenerativen erkrankungenInfo
- Publication number
- EP1372644A2 EP1372644A2 EP02730112A EP02730112A EP1372644A2 EP 1372644 A2 EP1372644 A2 EP 1372644A2 EP 02730112 A EP02730112 A EP 02730112A EP 02730112 A EP02730112 A EP 02730112A EP 1372644 A2 EP1372644 A2 EP 1372644A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- radical
- unsubstituted
- monosubstituted
- general formula
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 title claims abstract description 26
- 238000000034 method Methods 0.000 claims abstract description 55
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims abstract description 36
- 238000004519 manufacturing process Methods 0.000 claims abstract description 21
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 239000003112 inhibitor Substances 0.000 claims abstract description 8
- -1 amine compounds Chemical class 0.000 claims description 108
- 150000001875 compounds Chemical class 0.000 claims description 36
- 125000005418 aryl aryl group Chemical group 0.000 claims description 32
- RTOFMMILZZGGNS-UHFFFAOYSA-N imidazo[1,2-a]pyridin-3-amine Chemical class C1=CC=CN2C(N)=CN=C21 RTOFMMILZZGGNS-UHFFFAOYSA-N 0.000 claims description 30
- 125000002947 alkylene group Chemical group 0.000 claims description 19
- 125000003118 aryl group Chemical group 0.000 claims description 19
- 125000000623 heterocyclic group Chemical group 0.000 claims description 19
- 229910052739 hydrogen Inorganic materials 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 19
- 239000002904 solvent Substances 0.000 claims description 16
- 238000006243 chemical reaction Methods 0.000 claims description 15
- 206010061218 Inflammation Diseases 0.000 claims description 14
- 230000004054 inflammatory process Effects 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 125000001072 heteroaryl group Chemical group 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000011877 solvent mixture Substances 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- 150000003930 2-aminopyridines Chemical class 0.000 claims description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims description 7
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 7
- 201000006474 Brain Ischemia Diseases 0.000 claims description 7
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 7
- 208000023105 Huntington disease Diseases 0.000 claims description 7
- 208000019695 Migraine disease Diseases 0.000 claims description 7
- 208000018737 Parkinson disease Diseases 0.000 claims description 7
- 206010040070 Septic Shock Diseases 0.000 claims description 7
- 229910052783 alkali metal Inorganic materials 0.000 claims description 7
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 7
- 206010008118 cerebral infarction Diseases 0.000 claims description 7
- 206010012601 diabetes mellitus Diseases 0.000 claims description 7
- 230000036303 septic shock Effects 0.000 claims description 7
- 201000009906 Meningitis Diseases 0.000 claims description 6
- 208000031888 Mycoses Diseases 0.000 claims description 6
- 208000002193 Pain Diseases 0.000 claims description 6
- ICSNLGPSRYBMBD-UHFFFAOYSA-N alpha-aminopyridine Natural products NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 230000004770 neurodegeneration Effects 0.000 claims description 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 6
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims description 5
- 206010052428 Wound Diseases 0.000 claims description 4
- 208000027418 Wounds and injury Diseases 0.000 claims description 4
- 230000005855 radiation Effects 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- FGTXRRBSVUUVLP-UHFFFAOYSA-N 7-methyl-2-thiophen-3-ylimidazo[1,2-a]pyridin-3-amine Chemical compound N1=C2C=C(C)C=CN2C(N)=C1C=1C=CSC=1 FGTXRRBSVUUVLP-UHFFFAOYSA-N 0.000 claims description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 3
- 239000002585 base Substances 0.000 claims description 3
- 239000000010 aprotic solvent Substances 0.000 claims description 2
- 238000009835 boiling Methods 0.000 claims description 2
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 claims description 2
- 238000007796 conventional method Methods 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- 239000003586 protic polar solvent Substances 0.000 claims description 2
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- RGIMJUQMHHIZTA-UHFFFAOYSA-N NC1=CN=C2N1C=CC=C2.NC1=CN=C2N1C=CC=C2 Chemical class NC1=CN=C2N1C=CC=C2.NC1=CN=C2N1C=CC=C2 RGIMJUQMHHIZTA-UHFFFAOYSA-N 0.000 abstract 1
- 150000003254 radicals Chemical class 0.000 description 28
- 125000000217 alkyl group Chemical group 0.000 description 22
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 19
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 19
- 239000004475 Arginine Substances 0.000 description 13
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 13
- 235000009697 arginine Nutrition 0.000 description 13
- 238000003556 assay Methods 0.000 description 13
- 125000002877 alkyl aryl group Chemical group 0.000 description 11
- 125000001424 substituent group Chemical group 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 150000005840 aryl radicals Chemical class 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 150000001299 aldehydes Chemical class 0.000 description 6
- 125000005213 alkyl heteroaryl group Chemical group 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 6
- 229960002173 citrulline Drugs 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 5
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 5
- 235000013477 citrulline Nutrition 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000013537 high throughput screening Methods 0.000 description 3
- 230000001678 irradiating effect Effects 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 238000005341 cation exchange Methods 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 210000001638 cerebellum Anatomy 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 229940126601 medicinal product Drugs 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- 125000001617 2,3-dimethoxy phenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- GAPFINWZKMCSBG-UHFFFAOYSA-N 2-(2-sulfanylethyl)guanidine Chemical compound NC(=N)NCCS GAPFINWZKMCSBG-UHFFFAOYSA-N 0.000 description 1
- PBKADZMAZVCJMR-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;dihydrate Chemical compound O.O.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O PBKADZMAZVCJMR-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- RBIGKSZIQCTIJF-UHFFFAOYSA-N 3-formylthiophene Chemical compound O=CC=1C=CSC=1 RBIGKSZIQCTIJF-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 description 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- ORLGLBZRQYOWNA-UHFFFAOYSA-N 4-methylpyridin-2-amine Chemical compound CC1=CC=NC(N)=C1 ORLGLBZRQYOWNA-UHFFFAOYSA-N 0.000 description 1
- JHCIPOTYPSMKIL-UHFFFAOYSA-N 7-methyl-2-thiophen-3-ylimidazo[1,2-a]pyridin-3-amine;hydrochloride Chemical compound Cl.N1=C2C=C(C)C=CN2C(N)=C1C=1C=CSC=1 JHCIPOTYPSMKIL-UHFFFAOYSA-N 0.000 description 1
- PQCAUHUKTBHUSA-UHFFFAOYSA-N 7-nitro-1h-indazole Chemical compound [O-][N+](=O)C1=CC=CC2=C1NN=C2 PQCAUHUKTBHUSA-UHFFFAOYSA-N 0.000 description 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 125000002059 L-arginyl group Chemical class O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NTNWOCRCBQPEKQ-YFKPBYRVSA-N N(omega)-methyl-L-arginine Chemical compound CN=C(N)NCCC[C@H](N)C(O)=O NTNWOCRCBQPEKQ-YFKPBYRVSA-N 0.000 description 1
- NTNWOCRCBQPEKQ-UHFFFAOYSA-N NG-mono-methyl-L-arginine Natural products CN=C(N)NCCCC(N)C(O)=O NTNWOCRCBQPEKQ-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- YUDRVAHLXDBKSR-UHFFFAOYSA-N [CH]1CCCCC1 Chemical compound [CH]1CCCCC1 YUDRVAHLXDBKSR-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 1
- 229950011175 aminopicoline Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000009131 signaling function Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to the use of substituted imidazo [1, 2-a] pyridin-3-yl-amide and imidazo [1, 2-a] pyridin-3-yl-amine compounds and their physiologically tolerable salts as inhibitors for the Nitric oxide synthase and for the production of medicaments and a process for their preparation.
- NO synthase nitrogen monoxide synthase
- the medicinal products are said to be suitable for the treatment of migraines, septic shock, newly rodegenerative diseases such as multiple sclerosis, Parkinson's disease, Alzheimer's disease or Huntington's disease, inflammation, inflammation pain, cerebral ischemia, diabetes, meningitis, arteriosclerosis, fungal diseases or for wound healing.
- substituted imidazo [1, 2-a] pyridin-3-yl amide and amine compounds of the general formula I below act as inhibitors on the nitrogen monoxide synthase and are particularly useful for the treatment of migraines and septic shock , neurodegenerative diseases such as multiple sclerosis, Parkinson's disease, Alzheimer's disease or Huntington's disease, inflammation, inflammation pain, cerebral ischemia, diabetes, meningitis, arteriosclerosis, fungal diseases or for wound healing.
- the present invention therefore relates to the use of at least one substituted imidazo [1, 2-a] pyridin-3-yl amide or amine compound of the general formula I,
- R 2 is an unsubstituted or at least monosubstituted ⁇ -d-alkyl radical, an unsubstituted or at least monosubstituted C2-8 alkenyl radical, an unsubstituted or at least monosubstituted C 2- 8 alkynyl radical, a C 3 -8- Cycloalkyl radical, one via a C- ⁇ .
- R 4 for H, for an unsubstituted or at least monosubstituted
- C ⁇ -8 alkyl radical an unsubstituted or at least monosubstituted C2-8 alkenyl radical, an unsubstituted or at least monosubstituted C2-8 alkynyl radical, a C 3-8 -cycloalkyl radical, a C 3-7 - heterocyclyl radical, an unsubstituted or at least monosubstituted aryl or heteroaryl radical, an a C ⁇ -8 alkylene group bonded C 3-8 cycloalkyl radical, a via a C- ⁇ alkylene substituted aryl or heteroaryl radical bonded group C 3-7 heterocyclyl group, an a C ⁇ - 8 alkylene group bonded, unsubstituted or mono- or, preferably an unsubstituted or at least monosubstituted alkyl radical C ⁇ -8 or an unsubstituted or at least monosubstituted aryl or heteroaryl radical, particularly preferably an unsubstitute
- R 5 is an unsubstituted or at least monosubstituted C ⁇ -8 alkyl group, an unsubstituted or at least monosubstituted C2-8 alkenyl radical, an unsubstituted or at least monosubstituted C2-8 alkynyl radical, a C 3 -8- Cycloalkyl radical, a C 3 bonded via a Ci- ⁇ -alkylene group.
- R 6 is an unsubstituted or at least monosubstituted C- ⁇ -8 alkyl group, an unsubstituted or at least monosubstituted C2-8 alkenyl radical, an unsubstituted or at least monosubstituted C2-8 alkynyl radical, a C 3-8 cycloalkyl radical, a bound via a Ci- ⁇ alkylene group C 3-8 cycloalkyl radical, an unsubstituted or at least monosubstituted aryl or heteroaryl residue or an a C ⁇ -8 - alkylene group bonded unsubstituted or at least monosubstituted aryl or heteroaryl radical, preferably represents an unsubstituted or at least monosubstituted C ⁇ -8 alkyl radical or an unsubstituted or at least monosubstituted or at least monosubstituted aryl or heteroaryl radical, preferably represents an unsubstituted or
- R 7 is an unsubstituted or at least monosubstituted C- ⁇ -8 alkyl group, an unsubstituted or at least monosubstituted C2-8 alkenyl radical, an unsubstituted or at least monosubstituted C2-8 alkynyl radical, a C3 - 8 cycloalkyl radical, an a C ⁇ -8 alkylene group bonded C 3-8 cycloalkyl radical, an unsubstituted or at least monosubstituted aryl or heteroaryl residue or an a C ⁇ -8 - alkylene group bonded unsubstituted or at least monosubstituted aryl or heteroaryl radical, preferably represents an unsubstituted or at least monosubstituted C ⁇ -8 alkyl radical or an unsubstituted or at least monosubstituted aryl or heteroaryl radical, preferably represents an unsubstituted or at least monosubstitute
- R 8 is an unsubstituted or at least monosubstituted C ⁇ -8 alkyl group, an unsubstituted or at least monosubstituted C2-8 alkenyl radical, an unsubstituted or at least monosubstituted C2-8 alkynyl radical, a C 3 -8- Cycloalkyl radical, a C 3-8 -cycloalkyl radical bonded via a Ci- ⁇ -alkylene group, an unsubstituted or at least monosubstituted aryl or heteroaryl radical, one via a -C -8 alkylene group bound, unsubstituted or at least monosubstituted aryl or heteroaryl radical, preferably -8 alkyl radical, or substituted for an unsubstituted or at least monosubstituted aryl or heteroaryl radical is an unsubstituted or at least mono-substituted C ⁇ ,
- Preferred -8- alkyl radicals are selected from the group consisting of methyl, ethyl, n-propyl, 2-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, n-pentyl, iso - pentyl, neo-pentyl, n-hexyl, 2-hexyl and n-octyl.
- Preferred C 2-8 alkynyl radicals are selected from the group consisting of ethynyl, propynyl (-CH-C ⁇ CH, -C ⁇ C-CH 3 ), butynyl, pentynyl, hexynyl and octynyl.
- the C ⁇ -8 alkyl radical, the C 2-8 alkenyl group or C 2-8 alkynyl moiety is present singly or multiply substituted, is (are) one or more hydrocarbon radical (s) preferably by a substituent selected from the group F, Cl, Br, I, CN, NH 2 , NH alkyl, NH aryl, NH heteroaryl, NH alkyl aryl, NH alkyl heteroaryl, NH heterocyclyl, NH alkyl OH , N (alkyl) 2 , N (alkyl-aryl) 2 , N (alkyl-heteroaryl) 2 , N (heterocyclyl) 2 , N (alkyl-OH) 2 , NO, NO 2) SH, S-alkyl, S- Aryl, S-heteroaryl, S-alkyl-aryl, S-alkyl-heteroaryl, S-heterocyclyl, S-alkyl-OH, S
- C 3-8 cycloalkyl radical encompasses cyclic hydrocarbons having 3 to 8 carbon atoms, which may be saturated or unsaturated, unsubstituted or at least simply substituted, the bond of the cycloalkyl radical to the basic structure of general formula I can take place via any ring member of the cycloalkyl radical.
- the C 3-8 cycloalkyl radical is preferably selected from the group cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopentenyl, cyclohexenyl, cycloheptenyl and cyclooctenyl.
- the C 3-8 cycloalkyl radical is particularly preferably a cyclohexyl radical.
- C 3-7 heterocyclyl radical includes within the meaning of the present invention, a 3-, 4-, 5-, 6- or 7-membered cyclic organic radical which contains at least 1, optionally also 2, 3, 4 or has 5 heteroatoms in the ring system, where the heteroatoms may be the same or different and the cyclic radical may be saturated or unsaturated, but not aromatic and may be unsubstituted or at least monosubstituted.
- the heterocyclyl radical can be bound to the basic structure of the general formula I via any ring member of the heterocyclyl radical.
- the heterocyclyl residue can also be part of a bi- or polycyclic system. Preferred heteroatoms are selected from the group consisting of nitrogen, oxygen and sulfur.
- the C 3-7 heterocyclyl moiety is selected from the group tetrahydrofuryl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, piperazinyl and morpholinyl.
- aryl radical means aromatic hydrocarbons which can also be condensed with further saturated, at least partially unsaturated or aromatic ring systems, the bond between the aryl radical and the basic structure of the general formula I being via any ring member of the aryl residue can take place. If the aryl radical has more than one substituent, these can be the same or different and can be in any and possible position of the aryl radical.
- the aryl radical is preferably selected from the group of unsubstituted or at least monosubstituted phenyl, anthracenyl, 1-naphthyl and 2-naphthyl.
- the aryl radical is particularly preferably selected from the group of phenyl, 3-hydroxyphenyl, 3-methoxyphenyl, 2,3-dihydroxyphenyl, 2,3-dimethoxyphenyl and 1-naphthyl.
- heteroaryl radical stands for a 5-, 6- or 7-membered cyclic aromatic radical which has at least 1, optionally also 2, 3, 4 or 5 heteroatoms, the heteroatoms being the same or can be different and the binding to the basic structure of the general formula I can take place via any and possible ring member of the heteroaryl radical. If the heteroaryl radical has more than one substituent, these heteroaryl substituents can be the same or different and can be present in any and possible position of the heteroaryl.
- the heterocycle can also be condensed with further saturated, at least partially unsaturated or aromatic ring systems. Preferred heteroatoms are selected from the group consisting of nitrogen, oxygen and sulfur.
- the heteroaryl radical is preferably selected from the group of unsubstituted or at least monosubstituted pyrrolyl, furyl, thienyl, pyrazolyl, imidazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyranyl, indolyl, indazolyl, purinyl, pyrimidinyl, indolizinyl, quinolinyl, isoquinol Quinazolinyl, carbazolyl, phenazinyl and phenothiazinyl.
- heteroaryl radicals are selected from the group pyridin-2-yl, pyridin-3-yl, furan-2-yl, furan-3-yl, 5-hydroxymethylene-furan-2-yl, 5-nitro-furan 2- yl, 5- [1,3] dioxolane-furan-2-yl, 5-carboxylic acid furan-2-yl, thien-2-yl (2-thiophene), thien-3-yl (3-thiophene ) and 5-carboxylic acid-2-thiophene (5-carboxylic acid thien-2-yl).
- the C 3-8 cycloalkyl, the C 3-7 heterocyclyl, the aryl or the heteroaryl radical is mono- or polysubstituted, we preferably include one or more, for example two, three or four times, Substitution of one or more hydrogen atoms of the ring system with a substituent selected from the group F, Cl, Br, I, CN, NH 2 , NH alkyl, NH aryl, NH heteroaryl, NH alkyl aryl, NH alkyl heteroaryl , NH-heterocyclyl, NH-alkyl-OH, N (alkyl) 2 , N (alkyl-aryl) 2 , N (alkyl-heteroaryl) 2 , N (heterocyclyl) 2 , N (alkyl-OH) 2 , NO, NO 2 , SH, S-alkyl, S-cycloalkyl, S-aryl, S-heteroaryl, S-alkyl-
- substituents particularly preferred substituents are selected from the group F, CF 3 , OH and O-CH 3 .
- substituents are selected from the group OH, O-CH 3 , CH 2 OH, NO 2 , CO 2 H, CO 2 ethyl and [1, 3] -dioxolane.
- cycloalkyl radicals particularly preferred substituents are CO 2 H or CO 2 ethyl.
- the use of the compound 7-methyl-2-thiophene-3-yl-imidazo [1, 2-a] pyrididin-3-yl-amine or a physiologically tolerable salt, preferably the corresponding hydrochloride, as an inhibitor for the is very particularly preferred nitric oxide synthase.
- the substituted imidazo [1, 2-a] pyridin-3-yl-amide and amine compounds of the general formula I or their physiologically tolerable salts have at least one center of asymmetry, they can be used in the form of their racemates, their pure enantiomers , their pure diastereomers or in the form of a mixture of at least two of the aforementioned stereoisomers.
- substituted imidazo [1,2-a] pyridin-3-yl amide and amine compounds of the general formula I can also be present in the form of a mixture of their enantiomers or diastereomers. These mixtures can have two or more of the respective stereoisomers in any mixing ratio.
- Chiral substituted imidazo [1, 2-a] pyridin-3-yl amide or amine compounds of the general formula I are preferably used in enantiomerically pure form.
- the present invention further provides a process for the preparation of substituted imidazo [1, 2-a] pyridin-3-yl-amine compounds of the general formula I given above, in which the radical R 3 is H and the radicals R 1 , R 2 and R 4 to R 7 have the meaning according to the general formula I given above, by at least one substituted 2-aminopyridine of the general formula
- radicals R 1 and R 2 have the meaning according to the general formula I given above, in solution with at least one aldehyde of the general formula III,
- radical R 4 has the meaning according to the general formula I, and at least one alkali metal cyanide reacted with microwave radiation and the compounds of the general formula I thus obtained in which the radical R 3 is H and the radicals R 1 , R 2 and R 4 to R 7 have the meaning according to the general formula I, if necessary, are purified by conventional methods known to the person skilled in the art and optionally isolated.
- the power at which the microwaves are radiated and the frequency of the microwaves radiated in can vary over a wide range.
- Microwaves are preferably irradiated with an output of 100 to 1200 watts, particularly preferably 100 to 250 watts.
- the frequency of the irradiated microwaves is preferably in the range from 850 to 22250 MHz, particularly preferably in the range from 915 ⁇ 25 MHz, 2450 ⁇ 13MHz, 5800 ⁇ 75 MHz or 22125 ⁇ 125 MHz.
- the reaction time for carrying out the process according to the invention can vary depending on a large number of parameters, for example the type of the particular compounds of the general formula II or III, the type of solvent or the reaction temperature.
- the optimum reaction time in each case can be determined by a person skilled in the art by simple preliminary tests.
- the reaction takes place at a temperature up to at most the boiling point of the solvent or solvent mixture used.
- the reaction or solvent mixture is particularly preferably carried out under reflux.
- the time at which the radiation of the microwaves begins and the duration of the microwave radiation can also vary.
- at least one substituted 2-aminopyridine of the general formula II and at least one aldehyde of the general formula III are first reacted with one another with irradiation with microwaves, the reaction mixture thus obtained is cooled and then with at least one alkali metal cyanide, if appropriate at elevated temperature implemented.
- a substituted 2-aminopyridine of the general formula II, an aldehyde of the general formula III and an alkali metal cyanide are reacted with one another in equimolar amounts.
- aldehydes of the general formula III given above can be used both in pure form and in the form of their addition compounds, in particular in the form of their bisulfite adducts.
- the alkali metal cyanide used in the process according to the invention is preferably potassium cyanide, sodium cyanide or mixtures thereof, particularly preferably potassium cyanide.
- the process according to the invention for the preparation of substituted imidazo [1, 2-a] pyridin-3-yl-amine compounds of the general formula I given above, in which the radical R 3 is H and the radicals R 1 , R 2 and R 4 to R 7 have the meaning according to the general formula I can be carried out both in non-polar and in polar solvents, it being possible for the polar solvents to be both protic and non-protic. Mixtures of the abovementioned solvents can also be used.
- Water or a water-based solvent mixture is preferably used as the solvent in the process according to the invention.
- the process according to the invention can be carried out both under normal pressure and under reduced or increased pressure. It can preferably be carried out at elevated pressure, particularly preferably at a pressure of up to 3 bar.
- substituted 2-aminopyridines of the general formula II and the aldehydes of the general formula III are generally available on the market or can be prepared by customary methods known to the person skilled in the art.
- the present invention also relates to a process for the preparation of substituted imidazo [1, 2-a] pyridin-3-yl amide compounds of the general formula I given above, in which the radical R 3 is SO 2 R 8 and the R 1 , R 2 and R 4 to R 8 have the meaning according to the general formula I by at least one compound of the general formula I in which the radical R 3 is H and the radicals R 1 , R 2 and R 4 to R 7 have the meaning according to the general formula I, with at least one compound of the general formula R 8 -SO 2 -OH, R 8 -SO 2 -X or R 8 -SO 2 -O-SO 2 -R 8 , in which X represents Cl, Br or I and the radical R 8 each has the meaning according to the general formula I, to give a compound of the general formula I in which the radical R 3 represents SO 2 R 8 and the radicals R 1 , R 2 and R 4 to R 8 have the meaning according to the general formula I and, if necessary, they have been converted by customary methods
- a non-polar, a polar, protic or a polar, non-protic solvent can preferably be used as the solvent.
- the temperature can vary over a wide range.
- the temperature is preferably 0 to 300 ° C., particularly preferably 5 to 250 ° C.
- the substituted imidazo [1, 2-a] pyridin-3-yl-amine and amide compounds can be prepared in high yield and within short reaction times by the process according to the invention.
- the compounds obtained by the process according to the invention are furthermore distinguished by a high purity, so that the process according to the invention is excellently suitable for the preparation of substance libraries by combinatorial chemistry.
- the substituted imidazo [1, 2-a] pyridin-3-yl-amide and amine compounds of the general formula I according to the invention can be isolated by the process according to the invention both in the form of the free base and as a salt.
- amine compound of the general formula I is usually obtained after its preparation by the process according to the invention described above and, if appropriate, subsequent workup by customary methods known to the person skilled in the art.
- the free base of the respective imidazo [1, 2-a] -pyridin-3-yl-amide or amine compound of the general formula I thus obtained or formed in-situ without isolation can then, for example by reaction with an inorganic or organic Acid, preferably with hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, p-toluenesulfonic acid, carbonic acid, formic acid, acetic acid, oxalic acid, succinic acid, tartaric acid, mandelic acid, fumaric acid, lactic acid, citric acid, glutamic acid or aspartic acid, converted into the corresponding, physiologically compatible become.
- the conversion of the respective imidazo [1, 2-a] pyridin-3-yl amide or amine compound of the general formula I into the corresponding hydrochloride can preferably also be carried out by adding a suitable organic solvent, such as, for example, butan-2- on (methyl ethyl ketone), dissolved compound of general formula I can be obtained as a free base with trimethylsilyl chloride (TMSCI).
- a suitable organic solvent such as, for example, butan-2- on (methyl ethyl ketone)
- TMSCI trimethylsilyl chloride
- substituted imidazo [1, 2-a] pyridin-3-yl amide and amine compounds of the general formula I according to the invention can be obtained in the form of their racemates or other mixtures of their various enantiomers and / or diastereomers by the preparation process according to the invention these are separated and, if necessary, isolated by customary methods known to those skilled in the art. Examples include chromatographic separation processes, in particular liquid chromatography processes under normal pressure or under elevated pressure, preferably MPLC and HPLC processes, and processes of fractional crystallization. Individual enantiomers, e.g. diastereomeric salts formed by HPLC on a chiral phase or by crystallization with chiral acids, such as (+) - tartaric acid, (-) - tartaric acid or (+) - 10-camphorsulfonic acid.
- chiral acids such as (+) - tartaric acid, (-) - tartaric acid or (+) - 10-camphorsulfonic acid.
- Another object of the present invention is the use of at least one substituted imidazo [1, 2-a] pyridin-3-yl amide or amine compound of the general formula I as an inhibitor for the nitrogen monoxide synthase for the production of a medicament for the treatment of Migraines, septic shock, neurodegenerative diseases, preferably multiple sclerosis, Parkinson's disease, Alzheimer's or Huntington's disease, inflammation, inflammation pain, cerebral ischemia, diabetes, meningitis, arteriosclerosis, fungal diseases or for wound treatment.
- the present invention also relates to the use of at least one substituted imidazo [1, 2-a] pyridin-3-yl amide or amine compound of the general formula I for the manufacture of a medicament for combating migraines, septic shock, neurodegenerative diseases, preferably multiple sclerosis, Parkinson's disease, Alzheimer's disease or Huntington's disease, Inflammation, inflammation pain, cerebral ischemia, diabetes, miningitis, arteriosclerosis, fungal diseases or for wound treatment.
- the corresponding pharmaceuticals can be in the form of liquid, semi-solid or solid pharmaceutical forms, for example in the form of injection solutions, drops, juices, syrups, sprays, suspensions, granules, tablets, patches, capsules, plasters, suppositories, ointments, creams, lotions, gels, emulsions, Aerosols or in multiparticulate form, for example in the form of pellets or granules, are present and can also be administered as such.
- the medicaments according to the invention usually contain further physiologically tolerable pharmaceutical auxiliaries, which can preferably be selected from Group consisting of customary carrier materials, fillers, solvents, diluents, surface-active substances, dyes, preservatives, disintegrants, lubricants, lubricants, flavors and binders.
- physiologically tolerable pharmaceutical auxiliaries can preferably be selected from Group consisting of customary carrier materials, fillers, solvents, diluents, surface-active substances, dyes, preservatives, disintegrants, lubricants, lubricants, flavors and binders.
- physiologically compatible excipients and the amounts to be used depends on whether the medicinal product is oral, subcutaneous, parenteral, intravenous, intraperitoneal, intradermal, intramuscular, intranasal, buccal, rectal or local, for example on infections on the skin or mucous membranes and to be applied to the eyes.
- Preparations in the form of tablets, dragees, capsules, granules, pellets, drops, juices and syrups are preferably suitable for oral administration, and solutions, suspensions, easily reconstitutable dry preparations and sprays are suitable for parenteral, topical and inhalative administration.
- the amount of the particular imidazo [1, 2-a] -pyridin-3-yl-amide or amine compound to be administered to the patient may vary and is dependent, for example, on the weight or age of the patient and on the Type of application, the indication and the severity of the disease.
- 0.1 to 5000 mg / kg, preferably 1 to 500 mg / kg, particularly preferably 2 to 250 mg, per kg body weight of the patient are usually at least one imidazo [1, 2-a] -pyridin-3-yl-amide or -amin compound of general formula I applied.
- This assay allows the percentage inhibition of NO synthase by a compound of the general formula I according to the invention to be determined by measuring the NOS activity when the compound acts. NO synthase is mixed together with radioactively labeled arginine and the respective compound of general formula I under suitable conditions. After stopping the NO formation reaction at a given point in time, the amount of unreacted arginine is determined directly or indirectly. The comparison of this amount with the amount of arginine remaining in a mixture of NOS and arginine remaining in a mixture of NOS and arginine without addition of a compound according to the invention and under otherwise identical conditions gives the percentage inhibition of NO synthase through the tested compound.
- This assay can be carried out as follows:
- the separation takes place via a filter plate membrane.
- This NOS assay is particularly suitable for high throughput screening (HTS) on microtiter plates (MTP).
- HTS high throughput screening
- MTP microtiter plates
- Radioactive arginine is used as the substrate in this HTS-NOS assay.
- the assay volume can be selected between 25 ⁇ l and 250 ⁇ l depending on the type of microtiter plate (MTP).
- MTP microtiter plate
- cofactors and coenzymes are added.
- the batches are incubated in this microtiter plate (assay MTP) according to step (a) at room temperature and, depending on the enzyme activity (units) used, is between 5 and 60 minutes.
- the plate is placed in a cell harvester, which is equipped with an MTP that has a cation exchange membrane as a filter base (filter MTP).
- NADPH tetrasodium salt
- Order No. 1585363 R ⁇ CHE company
- Enzyme preparation buffer 50 mM Tris-HCl with 1 mM EDTA: The pH of the
- Buffer was set to 7.4 at 4 ° C.
- Incubation buffer 50 mM HEPES with 1 mM EDTA; 1, 25 mM CaCl 2 and 1 mM dithiothreitol.
- the pH of the buffer was adjusted to 7.4 at 25 ° C.
- Rat cerebelli were used as the starting tissue. The animals were anesthetized and sacrificed, the brain tissue, the cerebellum, was dissected out, 1 ml of enzyme preparation buffer (4 ° C.) was added per rat cerebellum, and the mixture was digested with a Polytron homogenizer for 1 min at 6000 rpm. This was followed by centrifugation at 4 ° C for 15 min at 20,000 g and then decanting off the supernatant and portioned freezing at -80 ° C (discarding the precipitate). incubation:
- the content of the assay MTP was then transferred into a 96-well cation exchanger MTP (filter MTP) with the aid of a 96-well cell harvester and suctioned off.
- a one-time wash with 200 ml H O (from one
- the plate was then dried in a drying cabinet at 60 ° C. for 1 h. Then the bottom side of the filter MTP was sealed exactly from below with a "back seal”. Then 35 ⁇ l scintillator were pipetted in per well. Furthermore, the top of the plate was sealed with a "top seal”. After a waiting time of 1 hour, the plate was measured on the ß counter.
- the substituted 2-aminopyridine of the general formula II was placed in water in a three-necked flask, an equimolar amount of the bisulfite adduct of the aldehyde of the general formula III was added and the mixture was heated under reflux for two hours while irradiating with microwaves.
- the reaction mixture was cooled to a temperature of 20 to 25 ° C and treated with an equimolar amount of aqueous potassium cyanide solution.
- the reaction mixture was then stirred for three hours at a temperature of 20 to 25 ° C and then overnight at 50 ° C.
- reaction mixture was optionally first filtered.
- the filtrate was then extracted with dichloromethane and diethyl ether, the combined extracts dried over sodium sulfate and concentrated.
- the crude product thus obtained was dissolved in 2-butanone, precipitated by adding half a molar equivalent of water followed by 1.1 equivalents of chlorotrimethylsilane and then stirring overnight.
- the primary amine prepared according to general procedure I was mixed with 20 equivalents of acetic anhydride in a Teflon vessel. The jar was capped and treated with 800 watts in the microwave for five to sixty minutes so that the temperature did not exceed 100 ° C. After cooling to 20 to 25 ° C, the reaction solution was poured into ice-cold, approximately five percent potassium carbonate solution and extracted with dichloromethane. The organic phase thus obtained was dried over sodium sulfate and / or potassium carbonate and concentrated. The crude product thus obtained was purified by column chromatography on silica gel and the corresponding hydrochloride was then precipitated in accordance with general working instructions I.
- Example 1 Example 1 :
- Example 1 The compound prepared according to Example 1 was tested in the HTS-NOS assay as described above. The inhibition of nitrogen monoxide synthase (10 ⁇ M) by the compound according to the invention according to Example 1 was 89%.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10117184 | 2001-04-05 | ||
DE10117184A DE10117184A1 (de) | 2001-04-05 | 2001-04-05 | Substituierte Imidazol[1,2-a]-pyridin-3-yl-amid- und -aminverbindungen |
PCT/EP2002/003796 WO2002080911A2 (de) | 2001-04-05 | 2002-04-05 | Verwendung substituierter imidazo[1,2-a]-pyridin-3-yl-amid- und imidazo[1,2-a]-pyridin-3-yl-aminverbindungen als arzneimittel zur behandlung von neurodegenerativen erkrankungen |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1372644A2 true EP1372644A2 (de) | 2004-01-02 |
Family
ID=7680631
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02730112A Withdrawn EP1372644A2 (de) | 2001-04-05 | 2002-04-05 | Verwendung substituierter imidazo[1,2-a]-pyridin-3-yl-amid-und imidazo[1,2-a]-pyridin-3-yl-aminverbindungen als arzneimittel zur behandlung von neurodegenerativen erkrankungen |
Country Status (9)
Country | Link |
---|---|
US (1) | US20040122044A1 (es) |
EP (1) | EP1372644A2 (es) |
JP (1) | JP2004531512A (es) |
CA (1) | CA2442986A1 (es) |
DE (1) | DE10117184A1 (es) |
HU (1) | HUP0400877A2 (es) |
MX (1) | MXPA03008894A (es) |
PL (1) | PL366437A1 (es) |
WO (1) | WO2002080911A2 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10310106A1 (de) * | 2003-03-06 | 2004-09-16 | Grünenthal GmbH | Substituierte Pyridot [1,2-a]pyrimidin-Verbindungen |
DE102004021716A1 (de) * | 2004-04-30 | 2005-12-01 | Grünenthal GmbH | Substituierte Imidazo[1,2-a]pyridin-Verbindungen und Arzneimittel enthaltend substituierte Imidazo[1,2-a]pyridin-Verbindungen |
DE102004044884A1 (de) | 2004-09-14 | 2006-05-24 | Grünenthal GmbH | Substituierte bizyklische Imidazo-3-yl-amin-Verbindungen |
ES2761180T3 (es) | 2005-12-23 | 2020-05-19 | Ariad Pharma Inc | Compuestos bicíclicos de heteroarilo |
FR2903107B1 (fr) | 2006-07-03 | 2008-08-22 | Sanofi Aventis Sa | Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique |
FR2903105A1 (fr) | 2006-07-03 | 2008-01-04 | Sanofi Aventis Sa | Derives de 2-benzoyl-imidazopyridines, leur preparation et leur application en therapeutique |
FR2903108B1 (fr) * | 2006-07-03 | 2008-08-29 | Sanofi Aventis Sa | Utilisation de derives d'imidazo[1,2-a] pyridine-2-carboxamides en therapeutique. |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4096264A (en) * | 1975-12-09 | 1978-06-20 | Merck & Co., Inc. | Certain substituted imidazo [1,2-a] pyridines |
US4105767A (en) * | 1977-03-28 | 1978-08-08 | Merck & Co., Inc. | Imidazo [1,2-a] pyridines substituted with a thienyl, thiazolyl, or thiadiazolyl group |
CA1164459A (en) * | 1980-11-11 | 1984-03-27 | Yung-Hsiung Yang | Process for preparing (imidazo¬1,2-a|pyridine- 2-yl)-carbostyril or -3,4-dihydrocarbostyryl derivatives |
DE3269604D1 (en) * | 1981-06-26 | 1986-04-10 | Schering Corp | Novel imidazo(1,2-a)pyridines and pyrazines, processes for their preparation and pharmaceutical compositions containing them |
FR2638161B1 (fr) * | 1988-10-24 | 1991-01-11 | Centre Nat Rech Scient | Nouvelles benzoyl-2 imidazo (1,2-a) pyridines et leurs sels, leur procede de preparation, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant |
US5244908A (en) * | 1990-07-30 | 1993-09-14 | Takeda Chemical Industries, Ltd. | Imidazopyridine derivatives and their pharmaceutical use |
DE4405378A1 (de) * | 1994-02-19 | 1995-08-24 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
US5912246A (en) * | 1995-02-15 | 1999-06-15 | Pharmacia & Upjohn Company | Imidazo 1,2-a!pyridines for the treatment of CNS and cardiac diseases |
JPH11505524A (ja) * | 1995-05-01 | 1999-05-21 | 藤沢薬品工業株式会社 | イミダゾ1,2−aピリジンおよびイミダゾ1,2−aピリデジン誘導体、および骨吸収阻害剤としてのその用途 |
US5912256A (en) * | 1996-06-20 | 1999-06-15 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
US6013654A (en) * | 1997-08-14 | 2000-01-11 | Pharmacia & Upjohn Company | Imidazo[1,2-A]pyridines for the treatment of CNS and cardiac diseases |
DE19948437A1 (de) * | 1999-10-08 | 2001-06-07 | Gruenenthal Gmbh | Am Sechsring substituierte, bicyclische Imidazo-3-aminderivate |
DE19948434A1 (de) * | 1999-10-08 | 2001-06-07 | Gruenenthal Gmbh | Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine |
DE19948438B4 (de) * | 1999-10-08 | 2004-04-15 | Grünenthal GmbH | Bicyclische Imidazo-3-aminderivate |
AU2001270297A1 (en) * | 2000-06-30 | 2002-01-14 | Neurogen Corporation | 2-phenylimidazo(1,2-a)pyridine derivatives: a new class of gaba brain receptor ligands |
DE10050663A1 (de) * | 2000-10-13 | 2002-04-18 | Gruenenthal Gmbh | Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung |
-
2001
- 2001-04-05 DE DE10117184A patent/DE10117184A1/de not_active Withdrawn
-
2002
- 2002-04-05 WO PCT/EP2002/003796 patent/WO2002080911A2/de not_active Application Discontinuation
- 2002-04-05 HU HU0400877A patent/HUP0400877A2/hu unknown
- 2002-04-05 JP JP2002578950A patent/JP2004531512A/ja not_active Withdrawn
- 2002-04-05 MX MXPA03008894A patent/MXPA03008894A/es unknown
- 2002-04-05 CA CA002442986A patent/CA2442986A1/en not_active Abandoned
- 2002-04-05 PL PL02366437A patent/PL366437A1/xx not_active Application Discontinuation
- 2002-04-05 EP EP02730112A patent/EP1372644A2/de not_active Withdrawn
-
2003
- 2003-10-03 US US10/677,960 patent/US20040122044A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO02080911A2 * |
Also Published As
Publication number | Publication date |
---|---|
CA2442986A1 (en) | 2002-10-17 |
WO2002080911A2 (de) | 2002-10-17 |
JP2004531512A (ja) | 2004-10-14 |
HUP0400877A2 (hu) | 2004-08-30 |
DE10117184A1 (de) | 2002-10-17 |
WO2002080911A3 (de) | 2003-09-25 |
US20040122044A1 (en) | 2004-06-24 |
MXPA03008894A (es) | 2003-12-08 |
PL366437A1 (en) | 2005-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1218378B1 (de) | Tert.-butyl-(7-methyl-imidazo[1,2-a]pyridin-3-yl)-amin-derivate | |
EP1326613B2 (de) | Verwendung von substituierten imidazo ¬1,2-a|pyridin-, -pyrimidin- und -pyrazin-3-yl-amin-derivaten zur herstellung von medikamenten zur nos-inhibierung | |
EP1339717B1 (de) | Neue carbamat-substituierte pyrazolopyridinderivate | |
EP1525202B1 (de) | Neue 2,5-disubstituierte pyrimidinderivate | |
EP1399423B1 (de) | Anthranilsäureamide mit heteroarylsulfonyl-seitenkette und ihre verwendung als antiarrhythmische wirkstoffe | |
EP1372647A2 (de) | VERWENDUNG VON SUBSTITUIERTEN IMIDAZO 1,2-a]-PYRIDINVERBINDUNGEN ALS ARZNEIMITTEL | |
DE10232571A1 (de) | 4-Aminosubstituierte Pyrimidinderivate | |
WO2006018184A2 (de) | Spirocyclische cyclohexan-derivate | |
EP1581490B1 (de) | Substituierte 5-aminomethyl-1h-pyrrol-2-carbons ureamide | |
EP1372644A2 (de) | Verwendung substituierter imidazo[1,2-a]-pyridin-3-yl-amid-und imidazo[1,2-a]-pyridin-3-yl-aminverbindungen als arzneimittel zur behandlung von neurodegenerativen erkrankungen | |
DE10244810A1 (de) | Neue Morpholin-überbrückte Indazolderivate | |
DE10247269A1 (de) | Substituierte C-Imidazo[1,2-a]pyridin-3-yl-methylamine | |
EP1549650B1 (de) | Substituierte c-imidazo[1,2-a]lpyridin-3yl-methylamine | |
EP1406888B1 (de) | Substituierte y-lactonverbindungen als nmda-antagonisten | |
EP1751101B1 (de) | Substituierte 5-Aminomethyl-1H-pyrrol-2-carbonsäureamide | |
EP1406610B1 (de) | Verwendung von substituierten gamma-lactonverbindungen als arzneimittel | |
EP1753757B1 (de) | Substituierte 2,5-diaminomethyl-1h-pyrrole | |
EP1603907B1 (de) | Substituierte pyrido(1,2-a)pyrimidine und ihre verwendung als nos-inhibitoren | |
EP1572653B1 (de) | Gesättigte und ungesättigte heteroarylcycloalkymethyl-amine als antidepressiva | |
DE10247271A1 (de) | Substituierte C-Imidazo[1,2-a]pyridin-3-yle | |
DE10108307A1 (de) | Substituierte Propan-1,3-diamin-Derivate | |
WO2004058248A1 (de) | Arzneimittel enthaltend substituierte 2,5-diaminomethyl-1h-pyrrole |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20031004 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20061101 |
|
RTI1 | Title (correction) |
Free format text: USE OF SUBSTITUTED IMIDAZO 1,2-A -PYRIDINE-3-YL-AMIDE AND IMIDAZO 1,2-A -PYRIDINE-3-YL-AMINE COMPOUNDS AS MEDICAMENTS |